Laurence Gorlick
Internal Medicine · Rolling Hills Estates, CANPI 1669411542
Payments from drug & device makers
Across 284 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$686
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$346
- Takeda Pharmaceuticals U.S.A., Inc.$343
- GSK$263
- Johnson & Johnson$178
- plus $1K from 29 others
What the payments were for
- Consulting fees$251%
- Food & beverage$4,43798%
- Education$481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 93 | $1,307 |
| AstraZeneca | 38 | $686 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $346 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $343 |
| GSK | 16 | $263 |
| Johnson & Johnson | 6 | $178 |
| Pfizer | 6 | $141 |
| Avanir Pharmaceuticals, Inc. | 18 | $109 |
| Amgen | 6 | $106 |
| Novo Nordisk | 5 | $97 |
| Lilly USA, LLC | 5 | $93 |
| Arbor Pharmaceuticals, Inc. | 6 | $92 |
| Bayer | 5 | $73 |
| Amarin Pharma, Inc. | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Merck | 3 | $50 |
| Biohaven Pharmaceuticals, Inc. | 2 | $46 |
| Neos Therapeutics, LP | 3 | $46 |
| Genentech USA, Inc. | 2 | $45 |
| LEO Pharma Inc. | 2 | $43 |
| Sanofi Pasteur Inc. | 2 | $39 |
| Corium, LLC | 2 | $37 |
| Almatica Pharma LLC | 2 | $30 |
| Cranial Technologies, Inc | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Gilead | 1 | $22 |
| Tanabe Pharma America, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Kaleo, Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $12 |
How this compares
$4,510 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $2,275 |
| Doxepin Hcl | 15 | $692 |
| Rosuvastatin Calcium | 25 | $488 |
| Mirtazapine | 17 | $339 |
| Clonazepam | 12 | $172 |
| Sumatriptan Succinate | 12 | $127 |
| Lorazepam | 17 | $77 |
| Carisoprodol | 13 | $46 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Rolling Hills Estates
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.